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Skin sensitizationAcrylic, Poly Methyl Methacrylate (PMMA) based polymers are found in many industrial, professional and
consumer products and are of low toxicity, but do contain very low levels of residual monomers and
process chemicals that can leach out during handling and use. Methyl Methacrylate, the principle
monomer is of low toxicity, but is a recognized weak skin sensitizer. The risk of induction of contact
allergy in consumers was determined using a method based upon the Exposure-based Quantitative Risk
Assessment approach developed for fragrance ingredients. The No Expected Sensitization Induction Level
(NESIL) was based on the threshold to induction of sensitization (EC3) in the Local Lymph Node Assay
(LLNA) since no Human Repeat Insult Patch Test (HRIPT) data were available. Categorical estimation of
Consumer Exposure Level was substituted with a worst case assumption based upon the quantitative
determination of MMA monomer migration into simulants. Application of default and Chemical-Speciﬁc
Adjustment Factors results in a Risk Characterization Ratio (RCR) of 10,000 and a high Margin of Safety for
induction of Allergic Contact Dermatitis (ACD) in consumers handling polymers under conservative expo-
sure conditions. Although there are no data available to derive a RCR for elicitation of ACD it is likely to be
lower than that for induction.
Crown Copyright  2014 Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction and/or levels of harmful substances that can migrate from them.Plastics play an important role in every aspect of modern life
from health and well-being, nutrition, accommodation and trans-
portation to safety and security, communication, leisure activities
and innovation. Plastics are involved in every phase of food
production, storage and preparation and regulations have been
established to control the substances used in their manufactureIn most other areas of application restrictive regulation has not
been considered necessary to date and it remains the responsibility
of the manufacturer/supplier to ensure safety in use.
Poly Methyl Methacrylate (PMMA) is a high production volume
plastic with a global market of almost 3 million tons in 2011 (CEH,
2012). Although the majority of Methyl Methacrylate (MMA)
monomer production is used by industry to manufacture acrylic
based polymers (acrylic sheeting, moulding compounds, surface
coatings, acrylic latexes (emulsions), lacquers, enamels, resins
impact modiﬁers and processing aids) some ﬁnds its way into pro-
fessional or skilled trade applications, such as the construction,
dental and medical industries (MPA, 2013). While residual level
of monomers in acrylic polymers is typically regulated according
their intended end-use such as food contact, dental, medical etc.,
there are many other types of acrylic-based polymers handled by
consumers in everyday life in the form of ﬁnished articles, coatings
etc., and therefore there is potential for more widespread
consumer dermal exposure.
In studies in animals, MMA is of low acute toxicity by all routes.
It is a skin and respiratory irritant but only a weak irritant to the
eyes. MMA is a weak skin sensitizer, but there is no convincing evi-
dence that it is a respiratory sensitizer in humans (Borak et al.,
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were noted at high doses including degenerative and necrotic
lesions in liver, kidney, brain, and atrophic changes in spleen and
bone marrow. MMA is clastogenic at high doses in vitrowith strong
toxic effects but this potential is not expressed in vivo, and there is
no relevant concern for carcinogenicity in humans and animals. It
has no effect on developmental toxicity, teratogenicity, embryo-
toxicity or fetotoxicity (OECD, 2007). In terms of safeguarding con-
sumer health from residual MMA monomer migrating from acrylic
polymers, the potential to cause Allergic Contact Dermatitis (ACD)
during the handling of acrylic-based polymer products is the lead
health effect of potential concern.
2. Objectives
Exposure-based Quantitative Risk Assessment (QRA) of fragrance
ingredients present in consumer products and known to cause ACD
has been described previously (Api et al., 2008) and although QRA of
food additives, or substances migrating from plastics in contact with
food, is well established both at national and international levels
(e.g., FDA, 1977; EU, 2012); to our knowledge the QRA of substances
migrating from polymers and causing ACD during consumer han-
dling of polymer products has not been reported.
The key steps in the Exposure-based QRA of fragrance
ingredients include the determination of benchmarks (No
Expected Sensitization Induction Level or NESIL); the application
of Sensitization Assessment Factors (SAF); and the estimation of
Consumer Exposure Levels (CEL) associated with product use. This
paper describes the application of a comparable approach to that
developed for fragrances to address very low levels of allergenic
monomers potentially migrating from acrylic polymers during
handling by consumers.
3. Mode of Action of MMA in the development of Allergic
Contact Dermatitis
The general processes that result in the development of sensiti-
zation comprises as key events the penetration into the skin of the
(pro)hapten and potential interaction with activating/deactivating
enzymes, reaction of hapten with skin protein to form antigen,
antigen encounter and recognition, antigen processing and trans-
port, and antigen presentation (IPCS, 2012).
MMA is a low molecular weight (100.12 g/mol) organic chemi-
cal that is readily absorbed through the skin giving it ready access
into the viable layers of the epidermis (CEFIC, 1993; Betts et al.,
2006). MMA itself is unlikely to be a complete antigen due to its
low molecular weight. The metabolic fate of MMA has been estab-
lished (Bratt and Hathway, 1977) and since the intact esters can
conjugate via vinylogous additive reactions, metabolic activation
is not thought to be required for MMA to become antigenic. Skin
however is rich in carboxylesterases (CES) and has been shown
to be a signiﬁcant site for local metabolism of topically applied
chemicals (Imai et al., 2013). Since the ﬁrst step of MMA metabo-
lism is hydrolysis of the ester bond by non-speciﬁc CES to form
methacrylic acid and methanol, neither of which is a recognized
contact sensitizer, metabolism is likely to be the mechanism of
detoxiﬁcation following dermal exposure (Jones, 2002). MMA, like
other acrylic and methacrylic esters, is a Michael acceptor electro-
phile and as such is capable of reaction with tissue nucleophiles via
Michael addition on the electrophilic Cb of the a,b-unsaturated car-
boxyl group (Freidig et al., 1999; Greim et al., 1995; McCarthy
et al., 1994). MMA is likely therefore to form covalent adducts with
carrier proteins, that can subsequently be recognized as antigenic
hapten-protein complexes (Natsch and Emter, 2008; Roberts
et al., 2008; Roberts and Aptula, 2008; Smith and Hotchkiss,
2001; OECD, 2012).4. Summary of contact allergy data on MMA
Numerous in vivo animal studies have been performed to char-
acterize the potential of MMA to cause skin sensitization.
There have been a large number of contact allergy tests in MMA
in animals reported in the literature including 12 Maximization
tests, 2 Buehler tests, 2 Freund’s complete adjuvant tests, 2 Split
adjuvant tests, 4 Polak tests and one Draize in guinea pigs; as well
as 2 ear sensitization tests and 3 Local Lymph Node Assays (LLNAs)
in mice. These have collectively been described by ECETOC (1995)
and Borak et al. (2011). In a representative Guinea Pig Maximiza-
tion Test (GPMT), using an intradermal induction concentration
of 5% Methyl Methacrylate, topical induction with 100% and
challenge with 1% and 5%, showed a 10% and a 50% positive sensi-
tisation rate, respectively (Cavelier et al., 1981). Results from other
Maximization tests showed positive reactions for 50–100%MMA as
well as non-sensitising responses. The reported negative results
appear to be mainly due to lower MMA concentration or volatile
vehicles being used. Non-adjuvant tests gave negative responses.
Three LLNAs have been reported with MMA. In an early version
of the LLNA, MMA caused no increase in proliferation of lympho-
cytes in the draining lymph nodes of guinea pigs after topical
application of MMA in acetone-olive oil (AOO) when measured
by a microscopic cell-counting method (Bull et al., 1985). More
recently, Betts et al. tested MMA in CBA/Ca mice using a method
consistent with OECD guideline 429 (OECD, 2002). In one test
MMA was dissolved in acetone, and in the other MMA was dis-
solved in an AOO mixture. MMA was weakly positive in both
assays, with EC3 values of 60% (w/v) and 90% (w/v), respectively
(Betts, 2004; Betts et al., 2006).
There are multiple case reports of contact allergy to MMA in
certain occupational environments (orthopaedic surgeons, dentists
and dental technicians and skilled trades using sealants) where
frequent and prolonged unprotected skin contact with monomer
containing preparations could occur. Single cases were also
reported in some medical, dental and cosmetic applications (EU
RAR, 2002; OECD, 2007). A critical review of the available literature
indicated that repeated exposure to undiluted MMA may lead to
skin sensitisation in susceptible persons but that the prevalence
is relatively low and cross reactivity to other methacrylates, reac-
tions to impurities, stabilizers, etc. may contribute. No clinical
studies equivalent to the Human Repeat Insult Patch Test (HRIPT)
have been reported with MMA so the dose–response or No
Observed Effect Level (NOEL) for induction of skin sensitization
in humans has not been established.5. The approach
Historically, regulatory assessment of skin sensitisation has
exclusively been aimed at the qualitative identiﬁcation of a
substance as an allergen, with the end result being classiﬁcation
either as a sensitizer or non-sensitizer.
More recently, it has been established that the induction as well
as elicitation of dermal sensitisation is a threshold phenomenon
(Kimber et al., 1999; Robinson et al., 2000). This, in principle,
enables a quantitative approach for the Risk Assessment (QRA).
Such an approach has been developed for fragrance ingredients
in consumer products, but can also be applied to other substances.
The ﬁrst step in the QRA is the determination of the benchmark
(No Expected Sensitization Induction Level or NESIL) as described
initially for fragrance ingredients (Api et al., 2008) and critically
reviewed by National Institute for Public Health and the Environ-
ment (ten Burg et al., 2010) and the WHO (IPCS, 2012).
Ideally, a NESIL would be based on a HRIPT tests done in classi-
cal design using several different induction doses and thus being
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No-Observed Effect Level (NOEL). This however is not available
for MMA and conducting such a study is not justiﬁable for a recog-
nized contact allergen on ethical grounds.
Despite there being numerous guinea pig tests with MMA,
methods such as the Buehler Assay or the Guinea Pig Maximisation
Test (GPMT) provide relatively poor information with regard to
sensitisation potency since they do not incorporate a dose–
response analysis, and activity is measured as frequency of
responses rather than as severity of responses (Basketter et al.,
1996, 2005a; Loveren et al., 2008). Therefore these data will not
be used for establishing a Point of Departure (PoD) for the QRA.
The data will be used, however, in a Weight of Evidence (WoE)
approach together with the available human data for MMA to
inform on the consistency of the database and on the potency of
MMA in humans and hence the reliability of the PoD.
There are 2 reliable LLNAs available for MMA, each using a
different vehicle and with at least 3 different doses sufﬁcient to
provide a dose–response curve for induction of sensitisation and
the determination of an EC3 value, the effective concentration of
a chemical leading to a 3-fold increase in proliferation of lymph
node cells compared to non-exposed controls (Basketter et al.,
1999). Therefore we will use the EC3 values from these studies
as the PoD for deriving the NESIL for MMA. Differences between
in exposure conditions and the way in which animals and humans
respond will be accounted for by using Sensitisation Assessment
Factors (SAFs) as detailed below.6. The Point of Departure (PoD) for MMA
As described above, MMA was weakly positive in both Local
Lymph Node Assays, with EC3 values of 90% (w/v) and 60% (w/v),
respectively (Betts, 2004; Betts et al., 2006). Since it is the dose
per unit area of a chemical that determines the level of sensitisat-
ion (Friedmann et al., 1983), these EC3 values have to be recalcu-
lated as dose per unit (skin) area in lg/cm2.
An estimate of the amount applied in a single application during
epidermal induction can be made based on the following assump-
tions: mouse ear assumed to be 1 cm2 area; volume used in the
studies by Betts and in the guideline LLNA is 25 lL (Garcia et al.,
2010; OECD, 2002).
Assuming the density of the liquid is 1, a conversion factor to be
applied to the EC3 (%) of 250 is calculated by converting 25 ll/cm2
into lg/cm2. The EC3 (%) is then converted to EC3 (lg/cm2) as
shown in the formula below:
EC3½%  250½lg=cm2% ¼ EC3½lg=cm2
For EC3 values of 90% (w/v) and 60% (w/v), respectively this
results in an EC3 of 2.25  104 lg/cm2 and 1.5  104 lg/cm2.7. Data extrapolation: Sensitization Assessment Factors (SAFs)
In line with established procedures for other areas of toxicolog-
ical Risk Assessment such as non-cancer endpoints, the use of
uncertainty factors is also accepted in immunotoxicity Risk Assess-
ment. The overall factors are based on various subfactors depend-
ing on the regulatory framework and/or the scope and purpose of
the Risk Assessment. Uncertainty factors applied to hypersensitiv-
ity generally include interspecies, intraspecies, matrix, use and
duration/frequency factors and may include database uncertainty
factors (IPCS, 2012). Although very conservative generally applica-
ble values for the individual factors exist, in order to prevent over-
conservatism by combining various subfactors, chemical speciﬁc
numerical values for each factor (generally ranging from 0.1 to
10) have to be derived on a case-by-case basis.7.1. Reliability of the POD
MMA has been shown to be a ‘‘weak’’ skin sensitizer in two
independent OECD guideline 429 Local Lymph Node Assays (LLNA)
in CBA/Ca mice requiring 60% (w/v) MMA monomer in acetone or
90% (w/v) MMA monomer in AOO (acetone: olive oil vehicle in a
4:1 ratio) to give a positive allergenic response in the mouse
(Betts et al., 2006).
The LLNA study (Betts et al., 2006) has been conducted equiva-
lent to an OECD Guideline 429 study (Skin Sensitisation: Local
Lymph Node Assay) as described by Kimber and Basketter, 1992.
Although there was no information on compliance with GLP, the
publication gives a thorough and detailed documentation of mate-
rials, methods and results from which the study can be judged as
being reliable without restrictions. Concerning the dose response
relationship, exceeding the minimum requirements of the most
recent version of the OECD guideline 429, 5 concentrations have
been tested and the two tests conducted with two different vehi-
cles gave results that were in the same order of magnitude. When
using a semi-quantitative approach, both results would lead to
classiﬁcation of MMA as a weak sensitizer.
The negative result obtained in the earlier study by Bull et al. is
consistent with the ﬁndings of Betts and co-workers if one takes
into account that the microscopic cell-counting method employed
is less sensitive than the 3[H]TdR incorporation method and the
level of stimulation observed by Betts only doubled the EC3 cut-
off with acetone (7.3%), and barely exceeded it in the case of
AOO (3.6%). Overall it may be concluded that the data in the LLNA
are internally consistent.
For the LLNA, it has been proposed that a vehicle-based mean
EC3 value can be used to derive a NESIL (Api et al., 2008). Use of
a vehicle-weighted mean, rather than the lowest EC value, could
be justiﬁed, because LLNA EC3 values, when tested repeatedly,
tend to vary within a factor of 2–3 from the mean value, and the
variability of the EC3 value caused by different vehicles leads to
uncertainty in the Risk Assessment that is taken into account in
setting the matrix assessment factor (IPCS, 2012). By giving prefer-
ence to the study with the lowest EC3 value we ensure a high level
of conservatism is maintained.
The other available contact allergy data on MMA although
unsuitable for deriving a NESIL can be used in a weight-of-evidence
approach to inform on the reliability of the POD.
In terms of the available test data in the guinea pig, MMA has
showed some positive reactions following induction with 50–
100% monomer in Maximization tests with typically negative
results at lower concentrations when non-Maximization protocols
were used. Overall this is indicative of a weak sensitizing potential
that is consistent with the EC3 value determined in the LLNA.
The available clinical data appear inconsistent at ﬁrst glance
with some papers reporting a high prevalence of ACD in some
medical, dental and cosmetic applications (EU RAR, 2002; OECD,
2007). However, in-depth review of these reports reveals a rela-
tively low overall prevalence in exposed individuals handing the
liquid monomer (Betts et al., 2006).
Altogether the data in animals and humans are consistent in
indicating a weak sensitizing potential for MMA and point to a high
level of conﬁdence in the POD. Thus for the reliability of the POD an
assessment factor of 1 is considered appropriate.
7.2. Assessment factors to address uncertainties in inter- and intra-
species variability
There has been a long-standing practice of using default assess-
ment factors to address uncertainties in inter- and intra-species
extrapolation in human health Risk Assessments with the
application of a total AF of 100 to the NOAEL observed in animal
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(Renwick, 1991, 1993; Renwick and Lazarus, 1998; U.S. EPA,
1988, 1993). In the last two decades there has been the develop-
ment of Data Derived Extrapolation Factors (DDEF) by the World
Health Organization (WHO) in 1994 and their guidance on the
development of Chemical-Speciﬁc Adjustment Factors (CSAFs) in
2005. More recently there has been the release of the European
Chemicals Bureau’s Technical Guidance Document for Risk Assess-
ment (ECB, 2003); the European Chemicals Agency’s Guidance on
information requirements and chemical safety assessment (ECHA,
2012) and U.S. EPA’s drafting of guidance for applying quantitative
data to develop data-derived extrapolation factors for interspecies
and intraspecies extrapolation (US EPA, 2011).
In context with this shift in paradigm we have endeavored to
develop chemical-speciﬁc assessment factors to address uncertain-
ties in inter- and intra-species variability.
7.2.1. Inter-species response variability
An interspecies uncertainty factor of 1 is conventionally applied
when the POD is derived from human data – for example, HRIPT
results for induction of skin sensitization. Using dose response
information from an LLNA for derivation of the NESIL differences
in sensitivity between mice and humans will have to be taken into
account by using appropriate inter-species SAF.
For systemic toxicity (non-cancer endpoints) historically an
assessment factor of 10 has been used to extrapolate from labora-
tory animals to humans (Renwick and Lazarus, 1998; WHO, 1994).
However, it is generally accepted that this only applies to the
extrapolation from rats to humans as it is comprised of two
sub-factors, a factor of 4 to account for toxicokinetics (basically
allometric scaling between the rat and humans) and a further
2.5, mainly for toxicodynamics (Renwick, 1991, 1993). For extrap-
olation from the mouse to humans an allometric scaling factor of 7
would apply (ECETOC, 2005). In contrast, for local toxicity end-
points such as skin irritation, no assessment factor was typically
applied (ECB, 2003; ECETOC, 2003, 2005).
For contact sensitisation, when using mouse LLNA data, a some-
what different approach is proposed:
Systemic toxicokinetic differences (e.g., allometric differences)
are not considered to play an important role in the development
of ACD since access of topically applied MMA to the target tissue
(the skin) does not involve systemic circulation, and due to the
short half-life of MMAwithin the body, it is unlikely to survive long
enough to be recirculated to the skin. However, local toxicokinetic
differences, associated with differences in skin penetration, and
toxicodynamic differences, associated with local metabolism,
may be important.
With regard to skin penetration, there is no data on the relative
permeability of mouse-ear and human palm skin to MMA. There is,
however, in vitro data showing that separated human abdominal
epidermis is 12.5 times less permeable than separated rat dorsal/
ﬂank epidermis to C14 radiolabelled MMA (453 ± 44.5 compared
with 5688 ± 223; lg cm2h1 ± SEM; Jones, 2002) and the use of
data generated in rodents as a surrogate for humans is generally
considered conservative because the skin of mice and rats tend
to show greater permeability to chemicals compared with that of
humans, with a 3- to 10-fold higher penetration often being
reported (Barber et al., 1992; Boogaard et al., 2000).
In term of comparative morphology there are obvious
differences between mouse ear skin and human palm skin. Skin
thickness in humans ranges from 521 lm (eyelid) to 1977 lm
(back) with the palms (1394 lm) being on the upper end of this
range, and comparable to that of the soles of the feet at 1565 lm
(Lee and Hwang, 2002). Palm skin also has a higher proportion of
epidermis than in other regions being comprised predominantly
of stratum corneum, which is the principal barrier against hydro-philic and lipophilic chemicals. In contrast the epidermal thick-
ness of 1–9 month old NMRI mice was calculated to be
between 10 and 15 lm (Kietzmann et al., 1990). Furthermore,
the presence of hair follicles in mouse-ear skin, but in human-
palm skin, might further enhance the penetration of lipophilic
chemicals like MMA.
Although there is no speciﬁc data on the relative permeabilities
of the two skin types to MMA, it appears highly unlikely that
human skin will be more permeable than mouse-ear skin.
As described earlier, MMA undergoes local metabolism by tis-
sue CES within the skin and this is likely to be the main mecha-
nism of detoxiﬁcation of dermally applied MMA. However, as
non-speciﬁc CES are ubiquitous in both mouse and human skin
(Jones, 2002) signiﬁcant interspecies differences are not to be
expected.
The biological process that takes place for the immune system
to respond to sensitisers is considered a practically similar process
across mammalian species and the mouse is considered a good
model for contact allergy in humans. It has further been shown
in a number of studies that mouse EC3 data when compared with
human NOEL´s from HRIPT tests in general closely correlate. On this
basis, the LLNA EC3 value has been suggested as a surrogate NOEL
in QRA by different authors (Basketter et al., 2000, 2005b;
Gerberick et al., 2001; Griem et al., 2003; Schneider and Akkan,
2004; Api et al., 2008) although there appears to be no consensus
on the need for, or magnitude of, an assessment factor for intraspe-
cies difference.
European Chemicals Agency (ECHA) guidance supporting
registration of chemicals under REACH recognizes that EC3 data
generally correlate well with human skin sensitisation thresholds
derived from historical predictive testing; however they go on to
state that cases exist where this correlation is poor with the two
values differing by 10-fold or more. Therefore ECHA recommends
use of a default SAF of ten for interspecies variation, unless there
is evidence (e.g., from a close analogue) of good correlation
between the EC3 and human NOAEL/LOAEL, in which case the
interspecies AF could be lowered. Griem et al. (2003) evaluated a
large data set of >30 different chemicals for which both human
and LLNA-data was available and on the basis of comparable
potency information proposed an Extrapolation Factor (EF) of 3.
API and coworkers did not include a SAF for interspecies differ-
ences for fragrance ingredients (API et al., 2008).
On the basis that human palm skin is very likely to be less per-
meable than mouse ear skin and that metabolism is unlikely to be
a moderating factor in the case of MMA, an interspecies Af of 1 is
considered appropriate. The degree of conﬁdence in this assess-
ment is moderate to high, particularly bearing in mind that the
lowest value from the LLNA data is used and additional testing in
animals and available human data is supporting the very low
potency.
7.2.2. Intra-species variability
This uncertainty factor is used to address the variability in
responses between individuals and protect particular sensitive
subpopulations such as children or elderly people.
Although it is now well understood that thresholds exist for
both the induction and the elicitation of allergic responses, such
as those of Allergic Contact Dermatitis, it must also be appreciated
that for any given allergen, these thresholds are not absolute val-
ues (Basketter et al., 2002). Differences in individual sensitivity
may be due to the condition of the skin at the site of contact or
individual differences in skin metabolism as these are relevant
factors which modulate the intradermal bioavailable dose of the
allergen (Felter et al., 2002). Additional factors that might contrib-
ute to the inter-individual variation in sensitivity could be related
to all individual molecular steps leading ﬁnally to the clinical
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bioavailability and metabolism, hapten formation (covalent
binding to proteins), epidermal inﬂammation via keratinocyte cell
signalling, dendritic cell activation and T cell proliferation as
explained in detail in diverse reviews (Gerberick et al., 2008;
Karlberg et al., 2008; Basketter and Kimber, 2010; Adler et al.,
2011). It is usually assumed that a default assessment factor of
10 is sufﬁcient to protect the larger part of the population, includ-
ing e.g., children and the elderly. For systemic toxicity, the use of a
default factor of 10 for the general population is currently sug-
gested by regulatory agencies and expert groups (WHO, 2005;
OECD, 2010; US EPA, 2011; ECHA, 2012).
A default value of 10 was also considered adequate to account
for individual susceptibility differences for the induction of skin
sensitisation (Felter et al., 2002, 2003).
The intraspecies uncertainty factor can be subdivided into tox-
icokinetic and toxicodynamic components. Furthermore, the
default value may be replaced by CSAFs when chemical speciﬁc
human toxicokinetic and toxicodynamic data are available.
In the case of MMA, we have to recognize that some informa-
tion exists on skin permeability, metabolism and protein-reactivity
that might suggest that toxicokinetic variability will likely be low.
Overall there is insufﬁcient data upon which to propose a CSAF and
therefore the default AF of 10 is considered appropriate.7.3. Matrix and differences in use pattern
This uncertainty factor is intended to account for differences in
vehicle or product form (matrix) between experimental conditions
used to determine the EC3/NOEL and real-life use situations. This
approach has originally developed for fragrance substances that
are usually formulated into a complex product matrix, which
might contain irritants or penetration enhancers (API et al., 2008).
According to Api et al. there are three key parameters for con-
sideration when extrapolating from the controlled experimental
situation to the real life scenario. They are site of contact, dermal
integrity, and occlusion.
The site of contact in the respective experimental setting (LLNA)
is the mouse ear whereas the typical site of consumer contact with
plastic articles is the palm of the hands. In the LLNA the mice were
exposed topically on the dorsum of both ears to 25 ll of various
concentrations of MMA in acetone or in an acetone/olive oil vehicle
daily for 3 consecutive days. Acetone disrupts the organization of
the lipid bilayer by selectively removing lipids from intercellular
lipid domains. Using acetone as a vehicle results in a substantial
reduction of the barrier function of the skin and therefore enhance
skin absorption for many substances (Tsai et al., 2001).In the other
LLNA study a mixture of acetone olive oil was used as a vehicle.
Olive oil has low volatility and would provide a lipophilic reservoir
on the skin surface aiding partitioning of MMA into the stratum
corneum and possibly retarding volatolisation. In contrast, con-
sumer exposure would typically involve intimate contact between
skin on the palms of the hands and the polymer product, perhaps
in the presence of sweat, for periods of between several minutes
to several hours. This combined with the previously established
conclusion that human palm skin is likely to be considerably less
permeable to MMA than mouse ear skin would indicate that the
experimental scenario in the LLNA is conservative of human expo-
sure and an overall factor of 1 is sufﬁciently conservative to
account for differences in use pattern.
It is however, recognized that for the calculation of the con-
sumer exposure, a 24 h continuous contact with no evaporation
was assumed and that more realistically the contact with plastic
products will be intermittent and of much shorter duration. Thus
a factor of 1 will be extremely conservative.8. Risk Assessment
Calculation of the risk quotient.
The two key elements for assessing the risk are the Acceptable
Exposure Level (AEL) and the comparison of that AEL to the
Consumer Exposure Level (CEL).8.1. Consumer Exposure Level (CEL)
Acrylic PMMA (Poly Methyl Methacrylate)-based polymers are
produced by industry using one of three free-radical initiation
polymerization processes i.e. bulk polymerization, emulsion
polymerization and solution polymerization (MPA, 2013).
Bulk or mass polymerization is the most common industrial
polymerization process and includes the manufacture of both
acrylic sheets and pellets (often referred to as resins). Cell cast
acrylic (PMMA) sheets typically contains 0.05–0.3% residual mono-
mer whereas extruded acrylic (PMMA) sheets contain 0.1–0.9% and
are used in the form of articles in windows, lighting, security,
safety, signage, retail displays and many other applications. Bulk
polymerized polymers are also extruded into pellets and contain
0.1–0.9% residual monomer and are used by industrial processors
in injection molding, compression molding and extrusion pro-
cesses to make acrylic articles for lighting, displays, signage, optical
and other applications.
Emulsion polymerized polymers contain 0.01–0.05% residual
monomer and are supplied in the form of solid latex particles or
liquid latexes or emulsions and used in the manufacture of
water-based adhesives and paints, as well as coatings for paper
and textiles.
Solution polymerized polymers typically contains 0.1–0.9%
residual monomer and are supplied as a polymer pellet, or in sol-
vent for the manufacture of varnishes, adhesives and coatings.
Although the handling of unprocessed acrylic sheets, polymer
pellets, emulsions and solvent-based polymer solutions is typically
restricted to industrial manufacturers and processors, some con-
sumers potentially could have frequent and daily contact with
end-processed and formulated acrylic polymers in the form of arti-
cles (kitchenware and utensils, reading glass lenses, LCD TV and
mobile phone screens etc.), as coatings on household or personal
items (paper and textiles etc.), or formulated into cleaning (pol-
ishes and waxes etc.) and Do-It-Yourself (water-based decorative
paints and corks etc.) products.
While acrylic polymers typically will only represent a small
portion of a formulated consumer product, in the case of solid
acrylic articles and surface coatings the acrylic polymer is likely
to represent the primary, if not only, surface that consumers will
be contacting on a routine basis. As such consumer handling of
acrylic articles and acrylic coated products and exposure to resid-
ual acrylic monomers migrating from these polymers could repre-
sent a signiﬁcant contribution to overall consumer exposure.
Franz and Brandsch reported extensive kinetic studies on the
migration of acrylic monomers (Methyl Acrylate, Ethyl Acrylate,
Butyl Acrylate, Methyl Methacrylate and n-Butyl Methacrylate)
from 11 representative acrylic polymers (produced by bulk (cast
sheet and pellets) and emulsion polymerization processes) using
CEN (European Committee for Standardization) methods for the
testing of food contact materials (CEN, 2004). Migration into stan-
dardized simulants for saliva, sweat, aqueous foods, fatty foods and
dry foods at 3 different temperatures (20 C, 40 C, 60 C) was
measured and the diffusion coefﬁcients of the monomers in the
polymer and the partition coefﬁcients between polymer and
contact media were determined. Migration of MMA and other
acrylic monomers from acrylic materials used for rigid plastics
applications (bulk polymerized polymers) was described as being
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coating applications (emulsion polymerized polymers) being
somewhat higher, but still very low when compared with other
typical polymers used for manufacture of food packaging materi-
als. Speciﬁcally, migration of residual acrylic (including MMA)
monomer from acrylic plaques into aqueous systems including sal-
iva and sweat simulant, as well as the skin contact simulant
Tenax, obeys Fickian laws of diffusion and was less than 15 lg/
dm2 (0.15 lg/cm2) over the ﬁrst 24 h of contact at 640 C (Franz
and Brandsch, 2013).
Considering the wide variety of acrylic articles and formulated
products available to consumers and the potential impact of differ-
ent life-styles and activity patterns it was decided to assume 24 h
continuous exposure as a worst case scenario for this assessment.
Accordingly a Consumer Exposure Level (CEL) of 15 lg/dm2
(0.15 lg/cm2) was established.
8.2. Acceptable Exposure Level (AEL)
The AEL is determined by dividing the Weight of Evidence
(WoE) NESIL by the total SAF. Whereas the WoE NESIL was derived
from the EC3 level derived from mouse LLNA as discussed above,
the SAFtotal is determined by the multiplication of all relevant indi-
vidual SAFs. Individual SAF have been assigned for the quality of
the database, for interspecies differences, for human inter-individ-
ual variability, for matrix effects and for use characteristics.
SAFtotalSAFqualitySAFinterspeciesSAFinterindividualSAFmatrixSAFuseSkin sensitisation speciﬁc AFsSAF for quality of
database1 Reliable and well documented
experimental data availableSAF for
interspecies
differences1 EC3 derived from mouse LLNAInter-individual
SAF10 Default AF for general populationSAF for vehicle or
matrix effects1 Matrix/vehicle used during animal
testing already reﬂects a worst-case
situationUse SAF 1 Skin contact with plastic products
will likely be intermittent and of
short durationSAF total 10After calculation of the SAFtotal, the AEL was calculated according to
the following equation (Api et al., 2008):
AEL ¼ WoE NESIL=SAFtotalWoE NESIL 1.5  104 lg/cm2
SAF total 10
AEL = NESIL/SAF 1.5  104/10
AEL 1500 lg/cm2/dayThe AEL is expressed in terms of dose/unit/day area. This Acceptable
Exposure Level for human general population is then compared to
the expected Consumer Exposure Level under normal conditions
of use. In the originally developed QRA for fragrance ingredients
for consumer products, the CEL (expressed as dose/unit area/day)
is a measure of exposure under intended and foreseeable conditionsof use (but not abuse) and takes account of the frequency of use,
habits, and practices (e.g., how consumers use the product), dura-
tion of use and amount of product used per application/use (Api
et al., 2008). For MMA as discussed above, migration of residual
acrylic (including MMA) monomer from acrylic plaques into diverse
simulants including saliva and sweat simulant, was less than
0.15 lg/cm2 over the ﬁrst 24 h of contact at 640 C (Franz and
Brandsch, 2013). This measured value was taken as a worst-case
for a scenario of 24 h continuous skin contact with polymerised
plastic articles and thus also taking into account any possible aggre-
gate exposure from the use of different products during the day.
Additional factors that might possibly lower the exposure to human
skin during use such as evaporation of MMA or rapid intradermal
detoxiﬁcation by CES as discussed above have not been taken into
account for the Risk Assessment thus also ensuring the worst-case
approach.
8.3. Risk Characterisation Ratio (RCR)AEL 1500 lg/cm2/day
CEL 0.15 lg/cm2/day
RCR (AEL/CEL) 10,000The Risk Characterisation Ratio (RCR) is derived by dividing the
Acceptable Exposure Level (AEL) by the Consumer Exposure Level
(CEL). The RCR of 10,000 indicates a high Margin of Safety i.e. the
measured rate of MMA being leaching over a 24 h period is many
times lower than the Acceptable Exposure Level despite the conser-
vative nature of the exposure assessment.
9. Discussion
The ability of chemicals to cause Allergic Contact Dermatitis
(ACD) is a common toxicological property of both naturally occur-
ring and industrial manufactured substances and to illustrate this
point more than 4000 environmental (natural and synthetic)
chemicals have been identiﬁed as potential contact allergens (De
Groot et al., 2008). This has to be appreciated in the context of
an estimated 15–20% of the general population of Western Europe
and North America suffering from contact allergy caused by one or
more substance (Thyssen et al., 2007; Peiser et al., 2012).
Society has, therefore, perhaps to recognize that many of the
conveniences considered necessary for modern life and that we
routinely take for granted, come at a non-zero risk. Often that risk
is very low-to-practically zero and does not require consideration,
but on occasion that risk may not be considered acceptable. On the
other hand, product de-selection on the basis of inherent hazard
where there is no risk to health would deprive society of beneﬁcial
products. Many fragrance materials, both naturally occurring and
man-made, are contact allergens and the fragrance and consumer
product industry has reﬁned Quantitative Risk Assessment (QRA)
approaches tailored for the wide variety of personal care and con-
sumer products on the market thereby ensuring appropriate risk/
beneﬁt considerations are taken before they are brought to market.
In the case of many polymer plastics that are not speciﬁcally
regulated by end-use regulations or standards, there has perhaps
been a general assumption that due to their high molecular weight
and the fact that they are often in the form of articles, that they are
safe. Certainly in the majority of cases this assumptions hold true,
but despite this there has been concern over the safety of plastics
and this has led to some calls for their restriction on the grounds of
the inherent hazard of the monomers used in their manufacture
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stances it is the chemical reactivity of the monomers themselves
that not only enable them to react and form polymers, but also
react with biological tissues, their toxicological properties often
go hand-in-hand with their utility to industry. It is important,
therefore, to develop QRA approaches, such as that described in
this paper, to reassure consumers and stakeholders that these
products are indeed safe and their continued use is justiﬁed.
The approach adopted here is based upon that developed for
fragrance materials. The two main adaptations are the inclusion
of a quantitative exposure estimate, to account for the release of
monomers from the polymer matrix, and the use of additional
adjustment factors, to address reliability of the Point of Departure
(PoD), and interspecies differences between mice and humans.
Where possible we have developed Chemical-Speciﬁc Adjustment
Factors (CSAFs) in-line with guidance on best practices.
In developing the approach we have consciously adopted a
tiered process to the quantiﬁcation of individual safety factors
whereby very conservative assumptions were made during the
ﬁrst tier of assessment, with a view to reﬁning these as and when
necessary. As it turned out the Margin of Safety (MOS) at the ﬁrst
tier was so large that further reﬁnement and the development of
less conservative, more realistic, assessment factors was not neces-
sary. It is envisaged, however, that this may not always be the case
and that possibly in other situations some reﬁnement of these
assumptions may be required before an acceptable MOS can be
achieved.
By applying an overall Sensitisation Assessment Factors (SAF) of
10 to the lowest EC3 value determined in a guideline LLNA study,
an AEL of 1500 lg/cm2/d was derived.
In terms of the exposure assessment we recognized that it was
extremely difﬁcult to be precautionary but sufﬁciently realistic at
the same time. This problem has already been recognized for con-
sumer products with dispersive uses and for fragrance ingredients,
such as citral, an exposure estimation mostly based on use catego-
ries is usually performed. Since we were aware of data indicating
extremely low migration of monomer from polymers we decided
to adopt a very conservative approach assuming extreme worst
case. In this scenario consumer contact with the polymer article
would be assumed to be continuous for 24 h, without loss by evap-
oration or metabolism by CES within the skin.
The exposure assessment was therefore taken as the measured
amount of residual acrylic monomer migrating from acrylic
polymer product into aqueous systems including saliva and sweat
simulant, as well as the skin contact simulant Tenax, over 24 h
i.e., 15 lg/cm2. A more realistic use scenario for handling plastic
products would perhaps be repeated exposures of much shorter
duration throughout the day.
9.1. Risk characterization
The resulting Risk Characterization Ratio (RCR), or the Accept-
able Exposure Level (AEL) divided by the Consumer Exposure Level
(CEL), of 10,000 indicates a high Margin of Safety for the induction
of contact allergy resulting from the handling of acrylic articles,
despite the conservative nature of the exposure assessment. More
realistically the RCR for consumer handling of acrylic articles may
be many orders of magnitude higher than that this.
While this high RCR indicates a low concern for ACD developing
during consumer handling of acrylic articles, it has to be recog-
nized that the threshold to elicitation of contact allergy usually
occurs at considerably lower levels than that for the induction of
allergy (Felter et al., 2002). As the NOEL for elicitation is typically
established in humans (IPCS, 2012) and this has not been estab-
lished for MMA, the Margin of Safety will likely be lower for indi-
viduals that are already sensitized to MMA. Notwithstanding this,the high Margin of Safety demonstrated for the induction of
contact allergy combined with the conservative nature of the expo-
sure assessment would suggest that the risk of elicitation during
consumer handling of acrylic articles would also be low.
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